Shares of Camtek plunged 7.1% to $104.34 in early trading Wednesday, extending a brutal four-week slide that has now erased roughly a third of the Israeli chip-inspection equipment maker's market value. The catalyst isn't a missed quarter — the company just posted record Q3 revenue of $161.3 million, up 28% year over year, and guided Q4 to approximately $180 million with 2027 revenue expected to exceed $800 million . The real pressure: Morgan Stanley on November 2 downgraded Camtek from Equal-Weight to Underweight, slashing its price target from $152 to $126 , arguing the good news is already baked into the stock price.
• Morgan Stanley Says the Growth Story Is Already Priced In. The bank raised its 2027 earnings estimate by 2% to reflect guidance but cut the valuation it's willing to pay to 20 times earnings from 23 times, arguing that Camtek's own target of $1.2 billion in revenue and $7.80 in earnings per share by 2029 already exceeds Morgan Stanley's estimates of $1.06 billion and $7.25 . In plain terms, the analyst believes the stock already reflects a best-case scenario, leaving little room for upside.
• The Services Bet Looks Like a Steep Climb. Morgan Stanley flagged that reaching Camtek's $140 million services and software revenue target would require a 2.4× increase in revenue per tool from 2026 to 2029 — a 34% compound annual growth rate . That's an ambitious leap for a company historically built on hardware sales, and any stumble would pressure margins.
• Competition in Chip Inspection Is Heating Up. Investors are focused on Morgan Stanley's concerns about rising competition in 2D chip inspection , the bread-and-butter technology Camtek uses to spot defects on semiconductor wafers. As larger rivals invest in similar tools, the debate is whether the current discount properly reflects execution risk in AI-driven advanced packaging and high-bandwidth memory orders .
• Insiders Were Selling Well Before the Downgrade. Six insiders — including the CEO, COO, and CFO — sold a combined $4.51 million in shares over the past 12 months, with zero insider purchases during that period . Those sales, executed in August near $170, look prescient now. Total insider selling over just three months reached $5.1 million .
The bottom line: Camtek's operations are humming — more than $800 million in orders booked since January and a P/E ratio of 186×, towering over its five-year median of 35× . Record revenue and a rich valuation have collided. Whether the stock is a bargain or a value trap now depends entirely on whether Camtek can grow fast enough to justify a price that already assumes it will.